Kornimate/medical-research-clean huggingface dataset:
medication review in patients on anti-parkinson therapy

Conditions: Parkinson's Disease

Summary: to identify patients within the community taking anti-parkinson medications in whom the diagnosis of parkinson's disease is incorrect and to supervise and clinically monitor the withdrawal of anti-parkinson medications in this patient group

step 1 - practice based pharmacist and medical review using database search for the following: * anti-parkinson drug therapy (excluding anticholinergic monotherapy). * disease codes to identify parkinson's disease and parkinsonism, and exclude other diagnoses where anti-parkinson therapy may be used, although both are expected to be very small numbers (pituitary tumour, restless leg syndrome) * to identify the duration of parkinsonism from the date of entry of the disease code. * pharmacy re-fill data to identify intermittent usage of treatment as an indicator of it being unlikely that the patient has idiopathic or dopa responsive parkinsonism. * to identify patients on monotherapy with anti-parkinson therapy e.g. selegiline for a prolonged duration as this is likely to suggest an alternative diagnosis. * to record drug dosage over time, e.g. on an annual basis, again to identify whether patients fit in with the expected rates of change for degenerative parkinsonism where increasing combinations of drugs at higher doses are used over time. step 2 - review of case records: · parkinson's disease nurse specialist and medical review of case records to identify additional clinical features of the condition and assist in identifying cases where it appears likely that anti-parkinson drug treatment is not helping the patient's condition. step 3 - specialist out-patient review and follow-up: · invitation to the patient to attend the combined neurology/medicine for the elderly movement disorder clinic service where scoring against diagnostic clinical criteria would be undertaken, and where appropriate tapering of anti-parkinson therapy gradually under continued specialist observation.

Eligibility criteria:
inclusion criteria: patients on anti-parkinson medication who: * have been on monotherapy for a prolonged period, or * use anti-parkinson medications intermittently, or * do not have the expected change in medication over time in keeping with degenerative parkinson's disease. exclusion criteria: * patients on anti-parkinson medication for reasons other than parkinson's disease. * patients with significant co-morbidity (end stage liver, cardiac or renal disease).

Keywords: medication diagnosis community
a pilot trial of acupuncture for knee osteoarthritis with differential functional status of acupoints

Conditions: Acupuncture; Knee Osteoarthritis; Randomized Controlled Trial

Summary: the investigators plan to undertake a rigorous multicentre randomised controlled trial, comparing acupuncture on sensitized acupoints with low/non-sensitive points or no acupuncture (waiting-list), to test if acupuncture on sensitized acupoints may result in improved treatment outcomes in patients with knee osteoarthritis (koa).the current pilot study aimed to assess the feasibility of performing the definitive randomised controlled trial.

patients in the intervention group received acupuncture treatment on the 5 most sensitized points/ acupoints.patients in the control group received acupuncture treatment on the 5 least /non-sensitized points. all other treatment settings were the same as in the intervention group.

Eligibility criteria:
inclusion criteria: * eligible patients are those aged 40 years or older who are diagnosed with koa and have signed the informed consent. * the diagnosis of koa will follow the diagnostic criteria according to the chinese guidelines for the medical management of osteoarthritis: * refractory knee pain for most days in the last month; * joint space narrowing, sclerosis or cystic change in subchondral bone (as indicated by x-ray); * laboratory examinations of arthritis: clear and viscous synovial fluid (≥2 times) and white blood cell count \< 2000/mm3; * age 40 years or older; * morning stiffness continues less than 30 minutes; * bone sound exists when joints was taking flexion and/or extension. a person is confirmed to be diagnosed with koa if meeting the either of the three criteria set: (1 and 2), or (1,3 and 5), or (1,4,5 and 6). exclusion criteria: patients will be excluded if they: * can not adhere to the study protocol in the future 6 months; * are diagnosed with conditions leading to skeletal disorders, such as tuberculosis, tumors or rheumatism of knee/bone joint, rheumatoid arthritis; * have sprain or other trauma; * are unable to walk properly due to foot deformity or pain; * are present with mental disorders; * have comorbidities including severe cardiovascular disease, liver or kidney impairment, immunodeficiency, diabetes mellitus or blood disorder; * females who are pregnant or lactating; * were using physiotherapy treatments for osteoarthritis knee pain; * had used intra-articular injection of glucocorticoid or viscosupplementation in the past 6 months; * received knee-replacement surgery; * were participating or had participated in the other clinical trials.
outcome of patients undergoing leadless pacemaker implantaton

Conditions: Bradyarrhythmias

Summary: observational study aimed to evaluate the rate and of complications related to lealdless pacemaker implantation.

observational, multicenter study enrolling consecutive patients undergoing leadless pacemaker implantation. procedure details, intraprocedural complications, and n-hospital outcomes will be recorded.

Eligibility criteria:
inclusion criteria: * patients with indication for leadless pacemaker implantation according to current guidelines on cardiac pacing. exclusion criteria: * inability to sign informed consent

Keywords: bradyarrhythmias leadless pacemaker complications
clinical and economic assessment of a pre-frail screening program

Conditions: Pre-frail; Elderly

Summary: the study intervention improves functional capacity and delays frailty status in pre-frail elderly subjects.


Eligibility criteria:
inclusion criteria: * more than 70 years consulting in primary care * non institutionalized * pre-frailty according to l.fried criteria (1 or 2 criteria) * signed informed consent exclusion criteria: * patient not able to stand by himself/herself * dementia * palliative care or life expectancy less than 6 months * blind patient * unstable clinical situation * participation in other programs, studies or trials for elderly people

Keywords: pre-frailty frail exercise nutritional assessment functional capacity
fatty liver disease collaborative research in china

Conditions: Fatty Liver; Fatty Liver, Alcoholic; Non-alcoholic Fatty Liver Disease

Summary: a multi-center, prospective cohort study on the natural history of fatty liver disease in china

this is a multicenter, prospective and open-enrollment epidemiologic study. all the patients with liver biopsy-proven macrovesicular steatosis (\>5%) will be enrolled in the baseline cross-sectional analysis. those who are either diagnosed as nafld or ald, if meeting all the inclusion and exclusion criteria, will be enrolled in the following cohort study, will be followed up after 1 year, 3 years and 5 years with a visit window of +1 month.

Eligibility criteria:
inclusion criteria: * clinically diagnosed fatty liver disease, confirmed by liver biopsy. * specific biopsy requirements: qualified biopsy specimen within 6 months, \>5% hepatocytes show macrovesicular steatosis under he staining and x10 microscope. * only patients with nafld or ald are eligible for the 5-year follow-up cohort study. * willing to participate in the long-term follow-up and cooperative. * able to provide informed consent file. exclusion criteria: * unable to provide informed consent. * patients are eligible for baseline cross-sectional analysis but not eligible for the cohort section, if having any of the following condition: 1. any end-stage liver disease. 2. any malignant tumor. 3. any infection of hepatitis virus or hiv. 4. any congenital liver disease such as wilson disease. 5. any other serious disease of projected survival \< 5 years. 6. combined nafld and ald.
family based treatment of early childhood obsessive compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: this study will evaluate a treatment program for young children with obsessive compulsive disorder (ocd) and their families.

childhood onset ocd is a serious condition that may be a predictor of illness in adulthood. to date, no ocd psychotherapy trials have specifically focused on early childhood. development of interventions for childhood onset ocd that address both developmental considerations and familial relationships is necessary. participants are randomly assigned to receive 12 sessions of either cognitive behavioral therapy (cbt) or relaxation training (rt) over the course of 14 weeks. the cbt treatment is designed to lessen anxiety by addressing specific ocd symptoms. the relaxation intervention addresses generalized feelings of anxiety with the expectation that ocd symptoms may benefit indirectly. the clarity, completeness, acceptability, and feasibility of both interventions is assessed. a 3-month post-treatment follow-up is also conducted.

Eligibility criteria:
inclusion criteria: * obsessive compulsive disorder (ocd)
comparison of nodal staging in endometrial cancer

Conditions: Endometrial Cancer

Summary: this study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging.


Eligibility criteria:
inclusion criteria: * surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with pelvic and aortic lymphadenectomy * histologically or cytologically confirmed endometrioid-type endometrial cancer confined to the uterine corpus * no clinical evidence of extra-uterine disease on pre-operative evaluation. * prior systemic chemotherapy is allowed so long as it was at least five years prior to study enrollment, and there is no evidence of disease after such therapy. * age ≥18 years. * life expectancy (estimated survival) of at least 6 months. * ast(sgot)/alt(sgpt) \< 3.0x upper limit of normal * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * gog/ecog performance status greater than 2 * non-endometrioid cell type * clinical evidence of disease that extends beyond the uterus, including the presence of suspicious aortic or inguinal nodes on imaging or clinical exam * previous vaginal, pelvic or abdominal irradiation * chemotherapy, hormone therapy or immunotherapy directed at the present disease * previous pelvic lymphadenectomy or retroperitoneal surgery * patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen * known allergy to iodine or indigocyanine green (icg) tracer, or allergic reactions to compounds of similar chemical or biologic composition * patients with uncontrolled intercurrent illness * patients with psychiatric illness/social situations that would limit compliance with study requirements * pregnant or lactating women

Keywords: sentinel node cancer endometrial intraoperative consultation
functional strength training and virtual reality in children with cp

Conditions: Cerebral Palsy

Summary: virtual reality (vr) has shown to be effective to improve arm function in children with cerebral palsy (cp). recently, functional strength training (fst) starts to show to improve arm function in patients with stroke but has not been extensively explored in children with cp. this pilot study is to examine the effect of fst and vr on improving arm function in children with cp as well as the neuroplasticity changes in the brain related to the level of improvement. ten children with spastic cp will be recruited to participate in this pilot study. children will be randomized to receive either vr of fst for 60 minutes per session x 3 sessions per week x 6 weeks at their home. all children will be evaluated prior to and immediately after the intervention at their home for clinical tests and at cabi for the mri measures. brain imaging data and clinical outcome measures including reaching kinematics, standardized fine motor assessment tool (peabody developmental motor scale-2nd edition), and daily use of affected hand (using revised pediatric motor activity log) will be evaluated. a physical therapist who is blinded to the status will conduct the assessment. the investigators anticipate children in both groups will improve their arm function after intervention; however, children in the vr group will have a better improvement as compared with children in the fst group.


Eligibility criteria:
inclusion criteria: * children with spastic cp are between ages 5-18 years; adults with spastic cp are between 19-30 years * diagnosed with spastic cp * have a manual ability classification system (macs) level i-iii * able to sit with trunk supported * are able to reach forward for more than half of their arm length * are able to follow three-step commands * are able to see video screen (with or without corrected vision); and * their primary caregiver is willing to follow the desired intervention "dosing" and all evaluation measurements, including mri. exclusion criteria: * they have received surgery or botulinum toxin type a injection in the training arm within the preceding 4 months or are scheduled to receive it during the planned study period, or * if they have a severe attention deficit or uncontrolled epilepsy which may possibly be triggered by the light or sound of the virtual reality games.

Keywords: virtual reality functional strength training arm function
metabolism and bariatric surgery study

Conditions: Insulin Resistance; Obesity

Summary: the purpose of this study is to determine if diet-induced weight loss causes different changes in hormones that control appetite and glucose control than surgery-induced weight loss. the overall research plan is a non-randomized prospective study of 3 different weight loss (wl) interventions and a lean and an obese healthy control group.

weight loss (wl) improves obesity-related co-morbidities such as type 2 diabetes mellitus (dm). unfortunately, wl through life-style interventions has a high degree of relapse and the lack of safe, effective and affordable therapies together with an increase in the prevalence of morbid obesity has led to a rise in bariatric procedures. clinical trials in patients with dm show that improvements in glycemia vary between procedures and occur in the following order: roux-en-y gastric bypass (rygb) \> sleeve gastrectomy (sg) \> laparoscopic adjustable gastric banding (lagb) \> medical/life-style therapy. this order mirrors the amount of wl with each intervention and is a major driver of glycemic improvement. the investigators have shown profound changes unique to rygb and sg in levels of hormones that make up the "gut-brain" and "enteroinsular" axes. the association of some of these hormones with insulin sensitivity (is) and glycemia, independent of wl strongly suggests that glycemic improvements after surgery occur in part through pathways that are distinct from just calorie restriction. this study builds on results showing that levels of fibroblast growth factor 19 (fgf19), a protein secreted by intestinal cells, are increased after rygb and sg but not after low calorie diet (lcd). this difference may affect hormones that control the stress response to weight loss. the investigators will explore differences in hormones of the gut that affect appetite, body weight, and stress response in healthy lean and obese individuals. obese individuals will also be studied before and after 15% body weight loss induced by lcd, rygb or sg, and again at 1 year after study enrollment.

Eligibility criteria:
inclusion criteria: men and women ages 18-65 years old exclusion criteria: 1. altered sleep-wake cycle 2. type 1 or 2 diabetes 3. previous bariatric surgery 4. lactose intolerance 5. any special diet restrictions. 6. use of medications that may affect body weight at screening or during a 3-month period prior. 7. untreated thyroid disease 8. other medical conditions like cushing's, acromegaly, hearth failure, crohn's disease, etc. 9. pregnancy 10. tobacco or opioid use 11. alcohol dependence 12. \> 3% weight change over the 3month period prior to screening 13. unwillingness to maintain current level of physical activity over duration of study period

Keywords: obesity insulin resistance bariatric surgery gastric bypass sleeve gastrectomy
magnesium sulphate in oblique subcostal tap block

Conditions: Postoperative Pain Management

Summary: the aim of this study is to evaluate the effect of adding different doses of mgso4 to bupivacaine via osctab block on postoperative pain control for 24 hours in patients scheduled for lc.

laparoscopic cholecystectomy (lc) is a gold standard for management of gallbladder stones. early and easily recovery, less operative morbidities, less postoperative pain, improved cosmetics, less hospitalization days and decreased cost are the superiorities of laparoscopic cholecystectomies over open surgical procedures. postoperative pain is the major obstacle for early postoperative ambulation and prolongs the hospital stay. moreover, it has been hypothesized that intense acute pain after lc may predict development of chronic pain (e.g., post laparoscopic cholecystectomy syndrome). so, aggressive perioperative pain prevention is mandatory. this pain is routinely managed using opiates, which has several side effects. transversus abdominis plane (tap) block is a regional anesthetic technique that has gradually become an alternative for postoperative pain control during laparoscopic abdominal surgeries. it involves the infusion of local anesthetic into the fascial plane of the abdominal wall. oblique subcostal transversus abdominis plane (osctap) block is an us-guided regional anesthesia technique that anesthetizes the nerves of the lower and upper anterior abdominal wall, specifically from t6 to l1. rafi et al and mcdonnell et al were the first to describe (osctap) block. they described an anatomical landmark technique and provided evidence of blockade to the mid/lower thoracic and upper lumbar spinal nerves as they travelled in the fascial plane between the transversus abdominis (ta) and internal oblique (io) muscles. evidence supporting the presence of (nmda) receptors in skin and muscles have led to the use of (mgso4) which is nmda antagonist via different routes.

Eligibility criteria:
inclusion criteria: * • patients programmed for elective lc. * american society of anesthesiologists (asa) physical state i or ii. * age over 18 years and less than 60 years old. * patients of both sex are included in the study. exclusion criteria: * • patient refusal. * known hypersensitivity to the study drugs. * body mass index \> 40 kg/m2. * inability to accurately describe postoperative pain to investigators. * opioid tolerance or dependence. * preexisting history of chronic pain. * history of renal, liver, cardiac, neuropsychiatric disorder problems. * bleeding or coagulation abnormality.
platelet rich fibrin(prf) injection for treatment of dental pulp exposure:randomized clinical trial

Conditions: Dental Pulp Exposure; Dental Caries

Summary: platelet rich fibrin(prf) obtained from patient from patient blood sample (before start of treatment)is injected in the site of exposure of exposure(intervention group) control group will receive normal pulp capping procedure by mta follow up will be one year

intervention group:patient with deep caries lesion ,free from sign and symptoms of irreversible pulpitis the blood sample will be taken before the beginning of dental treatment..prf will be obtained by blood centrifugal and injected in the site of exposure covered by glass ionomer restoration control group: patient with same condition will receive pulp capping procedure by mta followed by glass ionomer restoration

Eligibility criteria:
inclusion criteria: * deep carious lesion- no sign of irreversible pulpitis exclusion criteria: * old age- periapical lesion-
study of alvr106 in patients with respiratory viral infections after hematopoietic cell and solid organ transplant

Conditions: Respiratory Tract Viral Infections; Human Metapneumovirus (hMPV) Infection; Parainfluenza (PIV) Infection; Respiratory Syncytial Viral (RSV) Infection; Influenza Infection

Summary: a study to evaluate alvr106; an allogeneic, off-the-shelf multi-virus specific t cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (rsv), influenza, human metapneumovirus (hmpv), and/or parainfluenza virus (piv) following hematopoietic cell transplant (hct) and solid organ transplant (sot).

the study hypothesis is that the administration of alvr106, multi-virus specific t cells, plus standard of care, to post hct or sot patients suffering from infection with any of the four targeted viruses (rsv, influenza, hmpv, and/or piv) will be safe and demonstrate shorter time to resolution of the respiratory viral infection (as measured by resolution of symptoms and viral load clearance in nasal swab) compared to patients treated with placebo. this trial will consist of two parts: part a is dose escalation and part b is cohort expansion.

Eligibility criteria:
inclusion criteria: * undergone hematopoietic cell transplantation (hct) ≥21 days or solid organ transplantation (sot) ≥28 days prior to study treatment administration * detection of at least 1 target virus of interest (ie, rsv, influenza, hmpv, and/or piv) * diagnosis of upper or mild lower respiratory tract infection exclusion criteria: * ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>0.5 mg/kg/day) * infection by novel coronavirus disease 2019 (covid-19) * for hct patients, evidence of grade \>2 gvhd; and for sot patients, any history or evidence of gvhd

Keywords: respiratory virus hematopoietic cell transplant upper respiratory tract infection bone marrow transplant human metapneumovirus infection parainfluenza respiratory syncytial virus (rsv) multi-virus specific t cells (vst) solid organ transplant (sot)
electric impedance tomography

Conditions: Stroke Volume

Summary: evaluation of electrical impedance tomography to non-invasively monitor stroke volume when compared to reference measurements performed via right heart thermodilution


Eligibility criteria:
inclusion criteria: * patients undergoing cardiac surgery which requires placement of pulmonary catheter * patients with right heart catheterization for diagnostic or therapeutic reasons exclusion criteria: * patient unable to understand the study * patient unable to provide written consent or refusing his/her participation * patient suffering from a severe valvular insufficiency * patient allergic to ecg electrodes